Tracey Lambert, MD

In recent years, the pharmaceutical landscape has seen the emergence of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) such as semaglutide and tirzepatide, offering promising outcomes in weight reduction for those struggling with obesity. Landmark trials demonstrated significant weight loss in obese individuals. In the STEP 1 and STEP 3 trials,Read

With the celebration of International Women’s Day on March 8th, it’s timely to review the differences in women’s health research and how that specifically affects investigations into treatments for overweight and obesity. Obesity and overweight—gender similarities and differences By 2022, 8 billion people over 18 (43%) were overweight globally, ofRead

With the massive interest in the use of glucagon-like peptide-1 (GLP-1) receptor agonists for the management of both Type 2 diabetes and obesity/overweight, it is timely to review the mode of action of these medications and that of an alternative GLP-1-stimulating nutraceutical. Production of GLP-1 After a meal, endogenous GLP-1Read